May 9 2022 – Alan Oliver has been named chief operating officer for Gastro Health, a national leading medical group specializing in digestive and liver health. His appointment became effective on May 2, 2022. A career focused on maximizing business operations and leading mergers and acquisitions, as well as organic growth, has led Oliver very naturally to Gastro Health which has experienced unprecedented national growth and expansion in the gastroenterology sector over the last five years.
Author: Praveen Suthrum
A complaint filed with the U.S. Department of Justice (DOJ) alleges that Alabama’s Medicaid program is illegally denying curative drug treatment for hepatitis C virus (HCV) infection to people with substance use disorder.
Applications are now open for the 2023 AGA Fellowship cohort. AGA is proud to formally recognize its exemplary members whose accomplishments and contributions demonstrate a deep commitment to gastroenterology through the AGA Fellows Program. Those in clinical practice, education, or research (basic or clinical) are encouraged to apply today.
ISFIYA, Israel, May 11, 2022 /PRNewswire/ — Check-Cap Ltd. (the “Company” or “Check-Cap”) (NASDAQ: CHEK) (NASDAQ: CHEKZ), a clinical stage medical diagnostics company advancing the development of C-Scan®, the first and only patient-friendly, preparation-free screening test to detect polyps before they may transform into colorectal cancer (CRC), today announced the initiation of its U.S. pivotal trial of C-Scan® at Mayo Clinic in Rochester Minnesota.
The GI Research Foundation, an established non-profit dedicated to raising funds to advance the science and treatment of digestive diseases, has presented its prestigious Joseph B. Kirsner Award to David T. Rubin, MD, the Joseph B. Kirsner Professor of Medicine; Chief of the Section of Gastroenterology, Hepatology & Nutrition; and Co-Director of the Digestive Diseases Center at the University of Chicago Medicine. A talented clinician, researcher, and educator of great personal character, Dr. Rubin embodies the legacy of Joseph B. Kirsner, MD, PhD, and has created an enduring legacy of his own.
Three years after a spinoff from Takeda, Phathom Pharmaceuticals has successfully crossed the FDA finish line with a drug it got from the Japanese pharma. The FDA cleared Phathom’s vonoprazan in two combinations to treat Helicobacter pylori infection, which typically affects the stomach or the small intestine, the company said Tuesday. Takeda has been selling the therapy in several Asian markets.
The encouraging uptick in screening rates for colorectal cancer came to a halt with the emergence of SARS-CoV-2 and COVID-19. The pandemic resulted in postponed screening, delayed diagnostic endoscopy and potentially an excess of cancers that otherwise could have been prevented. Gastroenterology & Endoscopy News explored how COVID-19 has affected colonoscopy—a major component of gastroenterology practices.
Editor’s note: Find the latest COVID-19 news and guidance in Medscape’s Coronavirus Resource Center. New data present further evidence that SARS-CoV-2 infection can settle in the gastrointestinal (GI) tract and that it can persist long after the infection has cleared the lungs.
The doctor–surgeon relationship can be tense. As gastroenterologists, we often want to exhaust every medical option before we call in a surgical consultation. Surgeons, on the other hand, tend to want to perform surgery sooner rather than later, before the patient’s condition deteriorates and risks surgical complications. Sometimes this battle of egos causes us to forget the real reason we do what we do—to care for the patient. And it’s not so much the battle of our egos collectively but a struggle with our own.
Some argue for more competition in healthcare to drive improvements in the system. Optimizing safe, effective, and value-laden patient care is of central importance to physicians and institutions. Thus, “healthcare utilities,” such as Civica Rx, a pharmaceutical company in Utah supplying hospitals since 2018, spring up and challenge “oligopolies,” traditional markets where a few companies dominate, and business as usual is the rule.